

## PROVINCIAL FUNDING SUMMARY

Siltuximab (Sylvant) for Multicentric Castleman's Disease (pCODR 10052)

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: July 8, 2015

This information is current as of October 23, 2020.

This document was revised on October 23, 2020 to correct an error with the funding status of siltuximab (Sylvant) in Newfoundland and Labrador.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Dec 1, 2016	Biopsy proven symptomatic HIV negative, HHV-8 negative, multicentric Castleman's disease • NOTE: A BCCA "Compassionate Access Program" request with appropriate clinical information for each patient must be approved prior to treatment.
AB	Under provincial consideration		
SK	Funded	Aug 2, 2017	Treatment of multicentric Castleman's disease (MCD) in patients who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative and who have an ECOG performance status $\leq 2$ .
MB	Funded	Dec 5, 2016	For the treatment of patients with: i) Multicentric Castleman's Disease and ii) Who are HIV negative and iii) Who are HHV-8 negative and iv) With an Eastern Cooperative Oncology Group performance status of 2 or less.
ON	Funded	Dec 22, 2016	Previously treated or untreated patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative and who have an ECOG performance status $\leq 2$ .
NS	Funded	February 1, 2020	For previously treated or untreated multicentric Castleman's disease in patients who are human immunodeficiency virus (HIV) negative, human herpes virus-8 (HHV-8) negative and who have an ECOG performance status of less than or equal to 2. Treatment should continue until treatment failure.

PROVINCE	STATUS	FUNDING DATE	FUNDING CRITERIA
NB	Funded	July 10, 2017	For previously treated or untreated multicentric Castleman's disease in patients who are human immunodeficiency virus (HIV) negative, human herpes virus-8 (HHV-8) negative and who have an ECOG performance status of less than or equal to 2. Treatment should continue until treatment failure.
NL	Under provincial consideration		
PEI	Under provincial consideration		

*Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.*